|
US563536A
(en)
|
|
1896-07-07 |
|
Bracket for swinging stages |
|
US914623A
(en)
|
1908-08-19 |
1909-03-09 |
Henry H Williams |
Process in the manufacture of generating-plates for x-ray machines.
|
|
US1051266A
(en)
|
1910-09-26 |
1913-01-21 |
George I Rockwood |
Apparatus for operating alarms or other devices.
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4897445A
(en)
|
1986-06-27 |
1990-01-30 |
The Administrators Of The Tulane Educational Fund |
Method for synthesizing a peptide containing a non-peptide bond
|
|
EP0281604B1
(en)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Single polypeptide chain binding molecules
|
|
DE3642912A1
(de)
|
1986-12-16 |
1988-06-30 |
Leybold Ag |
Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
CA1341245C
(en)
|
1988-01-12 |
2001-06-05 |
F. Hoffmann-La Roche Ag |
Recombinant vaccinia virus mva
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
US5744166A
(en)
|
1989-02-25 |
1998-04-28 |
Danbiosyst Uk Limited |
Drug delivery compositions
|
|
US5100587A
(en)
|
1989-11-13 |
1992-03-31 |
The United States Of America As Represented By The Department Of Energy |
Solid-state radioluminescent zeolite-containing composition and light sources
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5179993A
(en)
|
1991-03-26 |
1993-01-19 |
Hughes Aircraft Company |
Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
|
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5976551A
(en)
|
1991-11-15 |
1999-11-02 |
Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and method of using the determinant
|
|
US5734023A
(en)
|
1991-11-19 |
1998-03-31 |
Anergen Inc. |
MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
DE69233782D1
(de)
|
1991-12-02 |
2010-05-20 |
Medical Res Council |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
US5747323A
(en)
|
1992-12-31 |
1998-05-05 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Retroviral vectors comprising a VL30-derived psi region
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
FR2707091B1
(fr)
|
1993-06-30 |
1997-04-04 |
Cohen Haguenauer Odile |
Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
|
|
US5820866A
(en)
|
1994-03-04 |
1998-10-13 |
National Jewish Center For Immunology And Respiratory Medicine |
Product and process for T cell regulation
|
|
JPH08510761A
(ja)
|
1994-03-07 |
1996-11-12 |
ザ・ダウ・ケミカル・カンパニー |
生物活性及び／又はターゲテッドデンドリマー複合体
|
|
FR2719316B1
(fr)
|
1994-04-28 |
1996-05-31 |
Idm |
Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
|
|
US5851806A
(en)
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
|
EP1548118A2
(en)
|
1994-06-10 |
2005-06-29 |
Genvec, Inc. |
Complementary adenoviral vector systems and cell lines
|
|
EP0769063A1
(en)
|
1994-06-27 |
1997-04-23 |
The Johns Hopkins University |
Targeted gene delivery system
|
|
US5972707A
(en)
|
1994-06-27 |
1999-10-26 |
The Johns Hopkins University |
Gene delivery system
|
|
FR2722506B1
(fr)
|
1994-07-13 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucleiques, preparation et utilisations
|
|
US7074904B2
(en)
|
1994-07-29 |
2006-07-11 |
Altor Bioscience Corporation |
MHC complexes and uses thereof
|
|
US5965541A
(en)
|
1995-11-28 |
1999-10-12 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
|
US5559099A
(en)
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
FR2727689A1
(fr)
|
1994-12-01 |
1996-06-07 |
Transgene Sa |
Nouveau procede de preparation d'un vecteur viral
|
|
AU4344696A
(en)
|
1994-12-21 |
1996-07-10 |
Novartis Ag |
Oligonucleotide-dendrimer conjugates
|
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5837520A
(en)
|
1995-03-07 |
1998-11-17 |
Canji, Inc. |
Method of purification of viral vectors
|
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
ATE285477T1
(de)
|
1995-06-07 |
2005-01-15 |
Inex Pharmaceutical Corp |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
ATE278794T1
(de)
|
1995-06-15 |
2004-10-15 |
Crucell Holland Bv |
Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
|
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
|
US5837511A
(en)
|
1995-10-02 |
1998-11-17 |
Cornell Research Foundation, Inc. |
Non-group C adenoviral vectors
|
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
|
WO1997035996A1
(en)
|
1996-03-25 |
1997-10-02 |
Transgene S.A. |
Packaging cell line based on human 293 cells
|
|
CA2177085C
(en)
|
1996-04-26 |
2007-08-14 |
National Research Council Of Canada |
Adenovirus e1-complementing cell lines
|
|
WO1998000524A1
(fr)
|
1996-07-01 |
1998-01-08 |
Rhone-Poulenc Rorer S.A. |
Procede de production d'adenovirus recombinants
|
|
US6211342B1
(en)
|
1996-07-18 |
2001-04-03 |
Children's Hospital Medical Center |
Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
|
|
US6348584B1
(en)
|
1996-10-17 |
2002-02-19 |
John Edward Hodgson |
Fibronectin binding protein compounds
|
|
DE69739961D1
(de)
|
1996-12-13 |
2010-09-23 |
Schering Corp |
Methoden zur Virus-Reinigung
|
|
FR2759382A1
(fr)
|
1997-02-10 |
1998-08-14 |
Transgene Sa |
Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
|
|
FR2760193B1
(fr)
|
1997-02-28 |
1999-05-28 |
Transgene Sa |
Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
|
|
WO1998039411A1
(en)
|
1997-03-04 |
1998-09-11 |
Baxter International Inc. |
Adenovirus e1-complementing cell lines
|
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
|
US6020191A
(en)
|
1997-04-14 |
2000-02-01 |
Genzyme Corporation |
Adenoviral vectors capable of facilitating increased persistence of transgene expression
|
|
ES2301198T3
(es)
|
1997-06-12 |
2008-06-16 |
Novartis International Pharmaceutical Ltd. |
Polipeptidos artificiales de anticuerpos.
|
|
WO1998056370A2
(en)
|
1997-06-13 |
1998-12-17 |
Johns Hopkins University School Of Medicine |
Therapeutic nanospheres
|
|
AU741130B2
(en)
|
1997-09-16 |
2001-11-22 |
Oregon Health Sciences University |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
|
US6232445B1
(en)
|
1997-10-29 |
2001-05-15 |
Sunol Molecular Corporation |
Soluble MHC complexes and methods of use thereof
|
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
|
US6113913A
(en)
|
1998-06-26 |
2000-09-05 |
Genvec, Inc. |
Recombinant adenovirus
|
|
US6440442B1
(en)
|
1998-06-29 |
2002-08-27 |
Hydromer, Inc. |
Hydrophilic polymer blends used for dry cow therapy
|
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
|
US7264958B1
(en)
|
1999-02-22 |
2007-09-04 |
Transgene, S.A. |
Method for obtaining a purified viral preparation
|
|
NZ515582A
(en)
|
1999-05-17 |
2003-11-28 |
Crucell Holland B |
Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
|
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
AU1013601A
(en)
|
1999-10-22 |
2001-05-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
|
DE19955558C2
(de)
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
|
US20030198953A1
(en)
|
2000-03-30 |
2003-10-23 |
Spytek Kimberly A. |
Novel proteins and nucleic acids encoding same
|
|
US20020192763A1
(en)
*
|
2000-04-17 |
2002-12-19 |
Jiangchun Xu |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
CN100537773C
(zh)
|
2000-11-23 |
2009-09-09 |
巴法里安诺迪克有限公司 |
改良安卡拉痘苗病毒变体
|
|
CA2430013C
(en)
|
2000-11-30 |
2011-11-22 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
|
US20150329617A1
(en)
|
2001-03-14 |
2015-11-19 |
Dynal Biotech Asa |
Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
WO2004006955A1
(en)
|
2001-07-12 |
2004-01-22 |
Jefferson Foote |
Super humanized antibodies
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
PL208712B1
(pl)
|
2001-08-31 |
2011-05-31 |
Avidex Ltd |
Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
|
|
AU2003242820A1
(en)
|
2002-03-14 |
2003-09-22 |
Exonhit Therapeutics S.A. |
Variants of human kallikrein-2 and kallikrein-3 and uses thereof
|
|
ES2288609T5
(es)
|
2002-04-19 |
2017-11-13 |
Bavarian Nordic A/S |
Virus vaccinia ankara modificado para la vacunación de neonatos
|
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
|
AU2003271904B2
(en)
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
CA2509980C
(en)
|
2002-11-12 |
2012-12-18 |
Albert B. Deisseroth |
Adenoviral vector vaccine
|
|
JP5052893B2
(ja)
|
2003-02-20 |
2012-10-17 |
アメリカ合衆国 |
ポックスベクターにおける新規の挿入部位
|
|
WO2004113571A2
(en)
|
2003-06-26 |
2004-12-29 |
Exonhit Therapeutics Sa |
Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
|
|
CA2537759C
(en)
|
2003-09-05 |
2015-03-24 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
GB2408507B
(en)
|
2003-10-06 |
2005-12-14 |
Proimmune Ltd |
Chimeric MHC protein and oligomer thereof for specific targeting
|
|
EP1687033A4
(en)
|
2003-11-12 |
2008-06-11 |
Us Navy |
STRENGTHENING IMMUNE RESPONSE INDUCED BY A VACCINE AND HETEROLOGOUS AMPLIFICATION PROTECTION WITH ALPHAVIRUS REPLICON VACCINES
|
|
EP1687334B1
(en)
|
2003-11-24 |
2014-01-08 |
MicroVAX, LLC |
Mucin antigen vaccine
|
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
|
PL1711518T3
(pl)
|
2004-01-23 |
2010-06-30 |
St Di Richerche Di Biologia Molecolare P Angeletti S P A |
Nośniki szczepionek pochodzące od szympansich adenowirusów
|
|
WO2006056766A2
(en)
|
2004-11-24 |
2006-06-01 |
St George's Enterprises Limited |
Diagnosis of prostate cancer
|
|
EP1683808A1
(en)
|
2005-01-25 |
2006-07-26 |
Het Nederlands Kanker Instituut |
Means and methods for breaking noncovalent binding interactions between molecules
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
DE102005028778A1
(de)
|
2005-06-22 |
2006-12-28 |
SUNJÜT Deutschland GmbH |
Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
|
|
AU2006291054B2
(en)
|
2005-09-12 |
2011-10-13 |
The Brigham And Women's Hospital, Inc. |
Recurrent gene fusions in prostate cancer
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
WO2007104792A2
(en)
|
2006-03-16 |
2007-09-20 |
Crucell Holland B.V. |
Recombinant adenoviruses based on serotype 26 and 48, and use thereof
|
|
PL1999154T3
(pl)
|
2006-03-24 |
2013-03-29 |
Merck Patent Gmbh |
Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
|
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
EP1878744A1
(en)
|
2006-07-13 |
2008-01-16 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
|
|
GB2442048B
(en)
|
2006-07-25 |
2009-09-30 |
Proimmune Ltd |
Biotinylated MHC complexes and their uses
|
|
GB2440529B
(en)
|
2006-08-03 |
2009-05-13 |
Proimmune Ltd |
MHC Oligomer, Components Therof, And Methods Of Making The Same
|
|
US7910565B2
(en)
|
2006-09-01 |
2011-03-22 |
Wisconsin Alumni Research Foundation |
Prostate cancer vaccine
|
|
NZ575388A
(en)
|
2006-10-06 |
2012-03-30 |
Bn Immunotherapeutics Inc |
Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
|
|
WO2008106615A1
(en)
|
2007-02-28 |
2008-09-04 |
Numenta, Inc. |
Spatio-temporal learning algorithms in hierarchical temporal networks
|
|
EP3061462B1
(en)
|
2007-07-02 |
2019-02-27 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
CA2702586C
(en)
|
2007-10-18 |
2017-08-01 |
Bn Immunotherapeutics Inc. |
Use of mva to treat prostate cancer
|
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
|
ES2567564T3
(es)
|
2007-11-19 |
2016-04-25 |
Transgene Sa |
Vectores oncolíticos de poxvirus
|
|
ES2564523T3
(es)
|
2007-12-19 |
2016-03-23 |
Janssen Biotech, Inc. |
Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
|
|
PL2235064T3
(pl)
|
2008-01-07 |
2016-06-30 |
Amgen Inc |
Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
|
|
WO2009111738A2
(en)
|
2008-03-06 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Single cycle replicating adenovirus vectors
|
|
WO2009127060A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
US9146238B2
(en)
|
2008-04-16 |
2015-09-29 |
The Johns Hopkins University |
Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
|
|
CN102076355B
(zh)
|
2008-04-29 |
2014-05-07 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
|
WO2010028099A1
(en)
|
2008-09-03 |
2010-03-11 |
The Johns Hopkins University |
Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
|
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
|
JP2012505654A
(ja)
|
2008-10-14 |
2012-03-08 |
ヤンセン バイオテツク，インコーポレーテツド |
抗体をヒト化及び親和性成熟する方法
|
|
JP5809978B2
(ja)
|
2008-10-31 |
2015-11-11 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
|
|
CN102307896B
(zh)
|
2008-10-31 |
2016-10-12 |
森托科尔奥索生物科技公司 |
基于iii型纤连蛋白结构域的支架组合物、方法及用途
|
|
KR20110111474A
(ko)
|
2009-01-09 |
2011-10-11 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
암에서의 반복적 유전자 융합체
|
|
BRPI1008018A2
(pt)
|
2009-02-02 |
2016-03-15 |
Okairos Ag |
ácidos nucleicos de adenovírus símio e sequências de aminoácidos, vetores contendo os mesmos e uso dos mesmos
|
|
JP5873335B2
(ja)
|
2009-02-12 |
2016-03-01 |
ヤンセン バイオテツク，インコーポレーテツド |
フィブロネクチンｉｉｉ型ドメインに基づくスカフォールド組成物、方法及び使用
|
|
US8394385B2
(en)
|
2009-03-13 |
2013-03-12 |
Bavarian Nordic A/S |
Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
|
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9539320B2
(en)
|
2009-05-15 |
2017-01-10 |
Irx Therapeutics, Inc. |
Vaccine immunotherapy
|
|
US20110300205A1
(en)
|
2009-07-06 |
2011-12-08 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
CA2777053A1
(en)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Human single-chain t cell receptors
|
|
ES2713852T3
(es)
|
2009-12-01 |
2019-05-24 |
Translate Bio Inc |
Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas
|
|
GB201002730D0
(en)
|
2010-02-18 |
2010-04-07 |
Uni I Oslo |
Product
|
|
US20170039314A1
(en)
|
2010-03-23 |
2017-02-09 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
|
WO2011119484A1
(en)
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
|
TWI688395B
(zh)
|
2010-03-23 |
2020-03-21 |
英翠克頌公司 |
條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
|
|
BR112012026766B1
(pt)
|
2010-04-20 |
2021-11-03 |
Genmab A/S |
Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
|
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
PT2591114T
(pt)
|
2010-07-06 |
2016-08-02 |
Glaxosmithkline Biologicals Sa |
Imunização de mamíferos de grande porte com doses baixas de arn
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
EP2590670B1
(en)
|
2010-07-06 |
2017-08-23 |
GlaxoSmithKline Biologicals SA |
Methods of raising an immune response by delivery of rna
|
|
RS54489B1
(en)
|
2010-07-06 |
2016-06-30 |
Glaxosmithkline Biologicals Sa |
LIPOSOMS WITH LIPIDS THAT HAVE IMPROVED PKA VALUE FOR RNA RELEASE
|
|
LT2590676T
(lt)
|
2010-07-06 |
2016-10-25 |
Glaxosmithkline Biologicals Sa |
Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms
|
|
EP2420253A1
(en)
|
2010-08-20 |
2012-02-22 |
Leadartis, S.L. |
Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
|
|
ES2935542T3
(es)
|
2010-08-31 |
2023-03-07 |
Glaxosmithkline Biologicals Sa |
Liposomas pequeños para la administración de ARN que codifica para inmunógeno
|
|
PL3970742T3
(pl)
|
2010-08-31 |
2022-09-19 |
Glaxosmithkline Biologicals S.A. |
Pegylowane liposomy do dostarczania rna kodującego immunogen
|
|
WO2012041968A1
(en)
|
2010-09-29 |
2012-04-05 |
Uti Limited Partnership |
Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
|
|
WO2012044999A2
(en)
|
2010-10-01 |
2012-04-05 |
Ludwig Institute For Cancer Research Ltd. |
Reversible protein multimers, methods for their production and use
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
EP2502934B1
(en)
|
2011-03-24 |
2018-01-17 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
|
|
CN103874706B
(zh)
|
2011-04-28 |
2016-06-08 |
贝勒医学院 |
在人类前列腺癌富集的作为生物标记物的再生嵌合rna
|
|
GB201108879D0
(en)
|
2011-05-25 |
2011-07-06 |
Isis Innovation |
Vector
|
|
CN103796680A
(zh)
|
2011-06-21 |
2014-05-14 |
约翰霍普金斯大学 |
用于增强针对赘生物的基于免疫的治疗的聚焦放射
|
|
EP2729126B1
(en)
|
2011-07-06 |
2020-12-23 |
GlaxoSmithKline Biologicals SA |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
US11896636B2
(en)
|
2011-07-06 |
2024-02-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
|
SG11201400250UA
(en)
|
2011-08-31 |
2014-03-28 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
CN107574154A
(zh)
|
2011-10-05 |
2018-01-12 |
金维克有限公司 |
猴(大猩猩)腺病毒或腺病毒载体及其使用方法
|
|
RU2014118727A
(ru)
|
2011-10-11 |
2015-11-20 |
Новартис Аг |
Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
|
|
US10344050B2
(en)
|
2011-10-27 |
2019-07-09 |
Genmab A/S |
Production of heterodimeric proteins
|
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
|
LT2794905T
(lt)
|
2011-12-20 |
2020-07-10 |
Medimmune, Llc |
Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
|
|
AU2013214776B2
(en)
|
2012-02-02 |
2017-11-09 |
Board Of Regents, The University Of Texas System |
Adenoviruses expressing heterologous tumor-associated antigens
|
|
US20160078168A1
(en)
|
2012-02-13 |
2016-03-17 |
Splicingcodes.Com |
Fusion transcript detection methods and fusion transcripts identified thereby
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
AU2013243953A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
PT2838917T
(pt)
|
2012-04-20 |
2019-09-12 |
Merus Nv |
Métodos e meios para a produção de moléculas similares a ig heterodiméricas
|
|
PE20150336A1
(es)
*
|
2012-05-25 |
2015-03-25 |
Univ California |
Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
|
|
KR20150038066A
(ko)
|
2012-07-30 |
2015-04-08 |
알렉스 와 힌 영 |
종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
|
|
EP3639851A1
(en)
|
2012-09-04 |
2020-04-22 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
|
EP2925348B1
(en)
|
2012-11-28 |
2019-03-06 |
BioNTech RNA Pharmaceuticals GmbH |
Individualized vaccines for cancer
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
MX2016000231A
(es)
|
2013-06-26 |
2016-10-05 |
Guangzhou Xiangxue Pharmaceutical Co Ltd |
Receptor de celulas t de la alta estabilidad y metodo de preparacion y aplicacion del mismo.
|
|
US10350275B2
(en)
|
2013-09-21 |
2019-07-16 |
Advantagene, Inc. |
Methods of cytotoxic gene therapy to treat tumors
|
|
EP3412304A3
(en)
|
2013-10-23 |
2019-03-20 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
|
|
AU2014347004B2
(en)
|
2013-11-05 |
2019-08-08 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
|
|
BR112016010224A2
(pt)
|
2013-11-05 |
2018-05-02 |
Cognate Bioservices, Inc. |
combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
|
|
CN105873902B
(zh)
|
2013-11-18 |
2019-03-08 |
阿克丘勒斯治疗公司 |
用于rna递送的可电离的阳离子脂质
|
|
DK3071697T3
(da)
|
2013-11-22 |
2020-01-27 |
Dnatrix Inc |
Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er)
|
|
JP6641276B2
(ja)
|
2013-11-28 |
2020-02-05 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
|
|
US20170106065A1
(en)
|
2013-12-31 |
2017-04-20 |
Bavarian Nordic A/S |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
|
|
US9884075B2
(en)
|
2014-01-16 |
2018-02-06 |
California Institute Of Technology |
Domain-swap T cell receptors
|
|
CA2939093A1
(en)
|
2014-02-14 |
2015-08-20 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
|
JP2017507672A
(ja)
|
2014-02-28 |
2017-03-23 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法
|
|
WO2015143221A1
(en)
|
2014-03-19 |
2015-09-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP4023249A1
(en)
|
2014-04-23 |
2022-07-06 |
ModernaTX, Inc. |
Nucleic acid vaccines
|
|
KR102499737B1
(ko)
|
2014-05-13 |
2023-02-13 |
버베리안 노딕 에이/에스 |
종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
|
|
JP2017515841A
(ja)
|
2014-05-13 |
2017-06-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
|
|
US20170158776A1
(en)
|
2014-05-15 |
2017-06-08 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
WO2015192068A1
(en)
|
2014-06-12 |
2015-12-17 |
The Johns Hopkins University |
Combinatorial immunotherapy for pancreatic cancer treatment
|
|
JP2017530114A
(ja)
|
2014-09-26 |
2017-10-12 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
|
|
EP3215164A1
(en)
|
2014-11-03 |
2017-09-13 |
Immures S.r.l. |
T cell receptors
|
|
EP3256156A1
(en)
|
2015-02-13 |
2017-12-20 |
Transgene SA |
Immunotherapeutic vaccine and antibody combination therapy
|
|
KR20180006916A
(ko)
|
2015-04-17 |
2018-01-19 |
메모리얼 슬로안-케터링 캔서 센터 |
고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
|
|
GB201506642D0
(en)
|
2015-04-20 |
2015-06-03 |
Ucl Business Plc |
T cell receptor
|
|
DK3326641T3
(da)
|
2015-04-22 |
2019-09-30 |
Curevac Ag |
Rna-holdig sammensætning til behandling af tumorsygdomme
|
|
AU2016253145B2
(en)
|
2015-04-23 |
2020-07-02 |
Nant Holdings Ip, Llc |
Cancer neoepitopes
|
|
US20190060484A1
(en)
|
2015-05-06 |
2019-02-28 |
Uti Limited Partnership |
Nanoparticle compositions for sustained therapy
|
|
US11559570B2
(en)
|
2015-05-15 |
2023-01-24 |
CureVac SE |
Prime-boost regimens involving administration of at least one mRNA construct
|
|
TWI806815B
(zh)
|
2015-05-20 |
2023-07-01 |
美商博德研究所有限公司 |
共有之ｇａｔａ３相關之腫瘤特異性新抗原
|
|
JP6752231B2
(ja)
|
2015-06-01 |
2020-09-09 |
カリフォルニア インスティテュート オブ テクノロジー |
抗原を用いて特異的集団に関してｔ細胞をスクリーニングするための組成物および方法
|
|
CN106714836A
(zh)
|
2015-06-05 |
2017-05-24 |
H·李·莫菲特癌症中心研究有限公司 |
Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
|
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
|
CN107847544B
(zh)
|
2015-07-20 |
2021-10-15 |
小利兰·斯坦福大学董事会 |
用多聚体结合试剂检测细胞表型和定量
|
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
|
EP3328394A4
(en)
*
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
PEPTIDE CONCATEMERIC EPITAOPE RNA
|
|
EA037295B1
(ru)
|
2015-08-20 |
2021-03-05 |
Янссен Вэксинс Энд Превеншн Б.В. |
Терапевтические вакцины против hpv18
|
|
WO2017070110A1
(en)
|
2015-10-19 |
2017-04-27 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
CN114404581A
(zh)
|
2015-10-22 |
2022-04-29 |
摩登纳特斯有限公司 |
癌症疫苗
|
|
WO2017075440A1
(en)
|
2015-10-30 |
2017-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Targeted cancer therapy
|
|
AU2016348391A1
(en)
|
2015-11-03 |
2018-05-17 |
Janssen Biotech, Inc. |
Antibodies specifically binding TIM-3 and their uses
|
|
US20190255186A1
(en)
|
2015-12-02 |
2019-08-22 |
Innovative Targeting Solutions Inc. |
Single variable domain t-cell receptors
|
|
CA3015650A1
(en)
|
2016-02-25 |
2017-08-31 |
Memorial Sloan Kettering Cancer Center |
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
|
|
MX2018010231A
(es)
|
2016-02-25 |
2019-06-06 |
Memorial Sloan Kettering Cancer Center |
Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
|
|
BR112018067565A2
(pt)
|
2016-03-04 |
2019-02-05 |
Univ New York |
vetores de vírus que expressam múltiplos epítopos de antígenos associados a tumor para induzir imunidade antitumor
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
BR112018070183A2
(pt)
|
2016-03-31 |
2019-04-16 |
Neon Therapeutics, Inc. |
neoantígenos e métodos de seu uso
|
|
CA3056212A1
(en)
|
2016-04-07 |
2017-10-12 |
Bostongene Corporation |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US10538786B2
(en)
|
2016-04-13 |
2020-01-21 |
Janssen Pharmaceuticals, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
ES2941411T3
(es)
|
2016-05-18 |
2023-05-22 |
Modernatx Inc |
Polinucleótidos que codifican interleucina-12 (IL12) y usos de los mismos
|
|
AU2017266929B2
(en)
|
2016-05-18 |
2023-05-11 |
Modernatx, Inc. |
Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
|
|
EP3458092A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
EP3463440A4
(en)
|
2016-05-27 |
2020-04-15 |
Etubics Corporation |
NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
|
|
US11427625B2
(en)
|
2016-06-14 |
2022-08-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
|
|
EP3472327B1
(en)
|
2016-06-20 |
2020-08-19 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
WO2018033254A2
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
|
TW202304970A
(zh)
|
2016-08-26 |
2023-02-01 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
|
CN110494159A
(zh)
|
2016-09-02 |
2019-11-22 |
扬森疫苗与预防公司 |
在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
|
|
HUE053236T2
(hu)
|
2016-09-12 |
2021-06-28 |
Targovax Oy |
Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére
|
|
JP7062003B2
(ja)
|
2016-09-28 |
2022-05-02 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法
|
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に対する二重特異性抗体
|
|
KR20190082226A
(ko)
|
2016-10-17 |
2019-07-09 |
신테틱 제노믹스, 인코포레이티드. |
재조합 바이러스 레플리콘 시스템 및 그의 용도
|
|
EP3532103A1
(en)
|
2016-10-26 |
2019-09-04 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
JP2020500847A
(ja)
|
2016-11-16 |
2020-01-16 |
プライムヴァックス イミュノ−オンコロジー，インク． |
癌の処置のための併用免疫療法
|
|
BR112019010565A2
(pt)
*
|
2016-11-23 |
2019-09-17 |
Gritstone Oncology Inc |
aplicação viral de neoantígenos
|
|
KR20190082850A
(ko)
|
2016-11-30 |
2019-07-10 |
어드박시스, 인크. |
반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
|
|
WO2018102585A1
(en)
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
|
|
BR112019011661A2
(pt)
|
2016-12-05 |
2020-01-07 |
Synthetic Genomics, Inc. |
Composições e métodos para aumentar expressão de gene
|
|
WO2018107011A1
(en)
|
2016-12-08 |
2018-06-14 |
City Of Hope |
P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
|
|
US10459372B2
(en)
|
2017-01-31 |
2019-10-29 |
Hewlett-Packard Development Company, L.P. |
Binary ink developer (BID) assembly for liquid electrophotography (LEP) printing device
|
|
NZ755780A
(en)
|
2017-02-01 |
2023-10-27 |
Modernatx Inc |
Rna cancer vaccines
|
|
US11229668B2
(en)
|
2017-02-07 |
2022-01-25 |
Nantcell, Inc. |
Maximizing T-cell memory and compositions and methods therefor
|
|
KR102111244B1
(ko)
|
2017-02-09 |
2020-05-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
이종 유전자의 발현을 위한 강력한 짧은 프로모터
|
|
MX2019009612A
(es)
|
2017-02-10 |
2019-11-12 |
Univ Rockefeller |
Metodos de elaboracion de perfiles especificos al tipo celular para identificar objetivos de farmacos.
|
|
WO2018161092A1
(en)
|
2017-03-03 |
2018-09-07 |
New York University |
Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
|
|
EP3595715A1
(en)
|
2017-03-17 |
2020-01-22 |
CureVac AG |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
US20230241207A1
(en)
|
2017-04-03 |
2023-08-03 |
Neon Therapeutics, Inc. |
Protein antigens and uses thereof
|
|
US20200121774A1
(en)
|
2017-04-19 |
2020-04-23 |
University Of Iowa Research Foundation |
Cancer vaccines and methods of producing and using same
|
|
CA3062591A1
(en)
|
2017-05-08 |
2018-11-15 |
Gritstone Oncology, Inc. |
Alphavirus neoantigen vectors
|
|
CN111107872A
(zh)
|
2017-05-12 |
2020-05-05 |
纪念斯隆-凯特林癌症中心 |
有用于癌症免疫疗法的牛痘病毒突变体
|
|
US20200188496A1
(en)
|
2017-06-02 |
2020-06-18 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Universal cancer vaccines and methods of making and using same
|
|
JP7334124B2
(ja)
|
2017-06-21 |
2023-08-28 |
トランジェーヌ |
個別化ワクチン
|
|
CN111108192B
(zh)
|
2017-07-05 |
2023-12-15 |
Nouscom股份公司 |
非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途
|
|
IL271965B2
(en)
|
2017-07-12 |
2023-03-01 |
Nouscom Ag |
Preparations containing a neoantigenic vaccine for the treatment of cancer
|
|
SG11202000250PA
(en)
*
|
2017-07-12 |
2020-02-27 |
Nouscom Ag |
A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
|
|
WO2019023566A1
(en)
|
2017-07-28 |
2019-01-31 |
Janssen Vaccines & Prevention B.V. |
METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
|
|
GB201713163D0
(en)
*
|
2017-08-16 |
2017-09-27 |
Univ Oxford Innovation Ltd |
HPV vaccine
|
|
JP7202362B2
(ja)
|
2017-08-24 |
2023-01-11 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
|
|
US11839655B2
(en)
|
2017-09-01 |
2023-12-12 |
Microvax, Llc |
Combination cancer therapy
|
|
AU2018333530B2
(en)
|
2017-09-13 |
2024-05-30 |
Biontech Cell & Gene Therapies Gmbh |
RNA replicon for expressing a T cell receptor or an artificial T cell receptor
|
|
KR20200076696A
(ko)
|
2017-11-03 |
2020-06-29 |
노우스콤 아게 |
백신 t 세포 인핸서
|
|
WO2019094396A1
(en)
|
2017-11-07 |
2019-05-16 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
JP7312412B2
(ja)
|
2018-01-05 |
2023-07-21 |
オタワ ホスピタル リサーチ インスティチュート |
改変オルトポックスウイルスベクター
|
|
AU2019205627B2
(en)
|
2018-01-06 |
2024-05-09 |
Emergex Vaccines Holding Limited |
MHC class I associated peptides for prevention and treatment of multiple flavi virus
|
|
JP2021516660A
(ja)
|
2018-01-11 |
2021-07-08 |
バイオンテック エールエヌアー ファーマシューティカルズ ゲーエムベーハー |
Ｒｎａの投与のための配合物
|
|
WO2019143949A2
(en)
|
2018-01-19 |
2019-07-25 |
Synthetic Genomics, Inc. |
Induce and enhance immune responses using recombinant replicon systems
|
|
EP3743084A4
(en)
|
2018-01-24 |
2021-12-08 |
Virogin Biotech Canada Ltd |
RECOMBINANT ANTIVIRAL VACCINES
|
|
CN111655845A
(zh)
|
2018-01-26 |
2020-09-11 |
联邦高等教育系统匹兹堡大学 |
代谢调节剂在肿瘤微环境中的表达以改善肿瘤的治疗
|
|
WO2019152922A1
(en)
|
2018-02-05 |
2019-08-08 |
Nant Holdings Ip, Llc |
Calreticulin and fusion proteins
|
|
US11376290B2
(en)
|
2018-03-14 |
2022-07-05 |
Wuhan Boweid Biotechnology Co., Ltd. |
Recombinant oncolytic virus, synthetic DNA sequence, and application thereof
|
|
US20210015878A1
(en)
|
2018-03-28 |
2021-01-21 |
Epicentrx, Inc. |
Personalized cancer vaccines
|
|
EP3773476A1
(en)
|
2018-03-30 |
2021-02-17 |
Arcturus Therapeutics, Inc. |
Lipid particles for nucleic acid delivery
|
|
TWI787500B
(zh)
|
2018-04-23 |
2022-12-21 |
美商南特細胞公司 |
新抗原表位疫苗及免疫刺激組合物及方法
|
|
GB201807932D0
(en)
|
2018-05-16 |
2018-06-27 |
Redchenko Irina |
Compositions and methods for inducing an immune response
|
|
EP3796927A4
(en)
|
2018-05-23 |
2022-04-20 |
Gritstone bio, Inc. |
SHARED ANTIGENS
|
|
CN112351793A
(zh)
|
2018-05-23 |
2021-02-09 |
磨石肿瘤生物技术公司 |
免疫检查点抑制剂共表达载体
|
|
CN112384205B
(zh)
|
2018-05-30 |
2024-05-03 |
川斯勒佰尔公司 |
信使rna疫苗及其用途
|
|
WO2019238023A1
(en)
*
|
2018-06-11 |
2019-12-19 |
Chineo Medical Technology Co., Ltd. |
Neoantigen vaccines and uses thereof
|
|
EP3587581A1
(en)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations for simian adenoviral vectors having enhanced storage stability
|
|
WO2020014539A1
(en)
|
2018-07-11 |
2020-01-16 |
Epicentrx, Inc. |
Methods and compositions for targeting cancer cells for treatment
|
|
WO2020022897A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
|
|
GB201812647D0
(en)
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
EP3850103A4
(en)
|
2018-09-15 |
2022-06-22 |
Memorial Sloan Kettering Cancer Center |
RECOMBINANT POXVIRUS FOR CANCER IMMUNOTHERAPY
|
|
US20210393757A1
(en)
|
2018-10-01 |
2021-12-23 |
The Wistar Institute |
Melanoma Canine Vaccine Compositions and Methods of Use Thereof
|
|
JP2022512595A
(ja)
|
2018-10-05 |
2022-02-07 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
|
|
WO2020073045A1
(en)
|
2018-10-05 |
2020-04-09 |
Nantcell, Inc. |
Cd40 and cd40l combo in an adenovirus vaccine vehicle
|
|
KR20210081325A
(ko)
|
2018-10-19 |
2021-07-01 |
노우스콤 아게 |
경골어류 불변 사슬 암 백신
|
|
JP2022506839A
(ja)
|
2018-11-07 |
2022-01-17 |
モデルナティエックス インコーポレイテッド |
Ｒｎａがんワクチン
|
|
AU2019374874A1
(en)
|
2018-11-07 |
2021-06-10 |
Gritstone Bio, Inc. |
Alphavirus neoantigen vectors and interferon inhibitors
|
|
JP7477888B2
(ja)
|
2018-11-15 |
2024-05-02 |
ノイスコム アーゲー |
個別化された癌ワクチンの作製のための癌変異の選択
|
|
EP3883599A1
(en)
|
2018-11-20 |
2021-09-29 |
Bavarian Nordic A/S |
Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
|
|
WO2020123912A1
(en)
|
2018-12-13 |
2020-06-18 |
Rhode Island Hospital |
Inhibition of asph expressing tumor growth and progression
|
|
CA3121430A1
(en)
|
2018-12-14 |
2020-06-18 |
Glaxosmithkline Biologicals Sa |
Heterologous prime boost vaccine compositions and methods
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109806390A
(zh)
|
2019-01-07 |
2019-05-28 |
康希诺生物股份公司 |
一种SamRNA疫苗及其制备方法
|
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
JP2022518399A
(ja)
|
2019-01-14 |
2022-03-15 |
ジェネンテック， インコーポレイテッド |
Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
|
|
KR20210118870A
(ko)
|
2019-01-21 |
2021-10-01 |
사노피 |
진행성 단계의 고형 종양 암에 대한 치료용 rna 및 항-pd1 항체
|
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
|
EP3721899A1
(en)
|
2019-04-08 |
2020-10-14 |
China Medical University |
Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
|
|
KR20220016137A
(ko)
|
2019-05-30 |
2022-02-08 |
그릿스톤 바이오, 인코포레이티드 |
변형된 아데노바이러스
|
|
WO2020247547A1
(en)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Cancer vaccine compositions and methods for use thereof
|